First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

被引：0
|
作者：
Tripathy, Debu
Sohn, Joohyuk
Im, Seock-Ah
Colleoni, Marco
Franke, Fabio
Bardia, Aditya
Harbeck, Nadia
Hurvitz, Sara
Chow, Louis
Lee, Keun Seok
Campos-Gomez, Saul
Vazquez, Rafael Villanueva
Jung, Kyung Hae
Carlson, Gary
Hughes, Gareth
Diaz-Padilla, Ivan
Germa, Caroline
Hirawat, Samit
Lu, Yen-Shen
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
[4] Ist Europeo Oncol, Unita Ric Senol Med, Milan, Italy
[5] CACONIjui, Hosp Caridade Ijui, Ijui, RS, Brazil
[6] Havard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[7] Univ Munich LMU, Breast Ctr, Munich, Germany
[8] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
[9] Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China
[10] Res Inst & Hosp, Natl Canc Ctr, Goyang, South Korea
[11] Inst Seguridad Social Estado Mexico & Municipios, Ctr Oncol Estatal, Toluca, Mexico
[12] Hosp Moises Broggi, Inst Catala Oncol, Barcelona, Spain
[13] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[14] Nova Pharmaceut Corp, E Hanover, NJ USA
[15] Novartis Pharma AG, Basel, Switzerland
[16] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS2-05
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Ribociclib (RIB) plus fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen K. L.
    Im, Seock-Ah
    Fasching, Peter A.
    DeLaurentiis, Michelino
    Petrakova, Katarina
    Bianchi, Giulia Valeria
    Esteva, Francisco J.
    Martin, Miguel
    Pivot, Xavier
    Vidam, Gena
    Wang, Yingbo
    Lorenc, Cristina Karen Rodriguez
    Miller, Michelle Kristine
    Taran, Tanya
    Jerusalem, Guy Heinrich Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer
    Jeong, Hyehyun
    Jeong, Jae Ho
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Koh, Su-Jin
    Cheon, Jaekyung
    Sohn, Joohyuk
    Kim, Gun Min
    Lee, Keun Seok
    Sim, Sung Hoon
    Park, In Hae
    Kim, Sung-Bae
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (04) : 917 - 924
  • [33] Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
    Moy, Beverly
    Neven, Patrick
    Lebrun, Fabienne
    Bellet, Meritxell
    Xu, Binghe
    Sarosiek, Tomasz
    Chow, Louis
    Goss, Paul
    Zacharchuk, Charles
    Leip, Eric
    Turnbull, Kathleen
    Bardy-Bouxin, Nathalie
    Duvillie, Ladan
    Lang, Istvan
    ONCOLOGIST, 2014, 19 (04): : 346 - 347
  • [34] Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2-advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.
    Hurvitz, Sara A.
    Im, Seock-Ah
    Lu, Yen-Shen
    Colleoni, Marco
    Franke, Fabio Andre
    Bardia, Aditya
    Harbeck, Nadia
    Chow, Louis
    Sohn, Joohyuk
    Lee, Keun Seok
    Campos Gomez, Saul
    Villanueva, Rafael
    Jung, Kyung Hae
    Chakravartty, Arunava
    Hughes, Gareth
    Gounaris, Ioannis
    Rodriguez-Lorenc, Karen
    Taran, Tetiana
    Tripathy, Debu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [35] MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC)
    Im, S. -A.
    Chow, L.
    Shao, Z.
    Tripathy, D.
    Bardia, A.
    Hurvitz, S.
    Harbeck, N.
    Colleoni, M.
    Franke, F.
    Germa, C.
    Hughes, G.
    McLean, L.
    Horan, M.
    Lu, Y. -S.
    ANNALS OF ONCOLOGY, 2015, 26 : 33 - 33
  • [36] Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen
    Fasching, Peter A.
    De Laurentiis, Michelino
    Im, Seock-Ah
    Petrakova, Katarina
    Bianchi, Giulia Val
    Esteva, Francisco J.
    Martin, Miguel
    Nusch, Arnd
    Sonke, Gabe S.
    De la Cruz-Merino, Luis
    Beck, J. Thaddeus
    Pivot, Xavier
    Vidam, Gena
    Wang, Yingbo
    Lorenc, Karen Rodriguez
    Miller, Michelle
    Taran, Tetiana
    Jerusalem, Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) : 2465 - +
  • [37] Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial
    Wang, S.
    Hong, R.
    Xu, F.
    Xia, W.
    Teng, Y.
    Ouyang, Q.
    Yuan, Z.
    Jiang, K.
    Lin, Y.
    Liu, X.
    Chen, Q.
    Wu, X.
    Shi, Y.
    Huang, J.
    An, X.
    Xue, C.
    Bi, X.
    Zheng, Q.
    Chen, M.
    Li, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S374 - S374
  • [38] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
    Verma, S.
    Gil-Gil, M.
    Hegg, R.
    Wheatley-Price, P.
    Kattan, J.
    Bourgeois, H.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option
    Gilabert, Marine
    Launay, Simon
    Goncalves, Anthony
    BULLETIN DU CANCER, 2014, 101 (03) : 325 - 333
  • [40] Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
    Slamon, D. J.
    Neven, P.
    Chia, S.
    Jerusalem, G.
    De Laurentiis, M.
    Im, S.
    Petrakova, K.
    Bianchi, G. Valeria
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    De la Cruz-Merino, L.
    Beck, J. T.
    Ji, Y.
    Wang, C.
    Deore, U.
    Chakravartty, A.
    Zarate, J. P.
    Taran, T.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 1015 - 1024
12345